Enter your registered email:
Indtast ny adgangskode:

The TACTIC project is co-funded by the European Commission under the HEALTH-Contract No. F3-2013-602771​

WP 4

Specifying pathophysiology and underlying mechanisms of Trauma Induced Coagulopathy

(TIC)

WP lead: Dr. Sisse Rye Ostrowski, Copenhagen

​Objectives:

  • Determine molecular mechanisms of TIC.

  • Identify biomarker signatures of coagulopathy that are predictive of outcome patterns.

To improve our understanding of the body’s acute response to injury TACTIC will determine patterns of different TIC biomarkers to:

  • Identify biomarker signatures associated with haemorrhagic coagulopathy (measurement of coagulation factors, natural anticoagulants and fibriniolysis markers in plasma samples from trauma patients).
  • Identify biomarker signatures associated with vasculopathic coagulopathy (measurement of biomarkers of sympathoadrenal activation and endothelial cell activation and damage in plasma samples from trauma patients).

The combined output of the haemorrhagic and vasculopathic coagulopathy biomarkers will be used in WP5 to enable the molecular description of different coagulopathic patients in relation to their functional coagulation status. Furthermore, the correlation of biomarkers with outcomes (e.g. patterns of organ dysfunction, infection) will be investigated.

TIC is heterogeneous in nature and the influence of genetic background is yet unknown. Here TACTIC will target genetic elements associated with vasculopathic coagulopathy to identify determinants that confer the adverse acute pathology (e.g. early TIC) and adverse patient outcome by:

Identify genetic polymorphisms that predispose patients to TIC & adverse outcomes (measurement of SNPs for α and β adrenergic receptor, thrombomodulin receptor, protein C system, syndecan-1, Angiopoietin 2, HMGB1 and TLR2 systems in DNA from trauma patients).

The SNPs identified to be significantly associated with early TIC or more adverse outcome will be prospectively evaluated for their predictive value. Further analysis of samples collected during the TACTIC RCT will be conducted to enable the refinement and testing of hypotheses as appropriate (Year 5). These results will provide substrate for further efforts to deliver novel diagnostic assays for the earlier and more accurate identification of patients at risk of TIC and developing more adverse outcomes.

Deliverables

Delivery date (month)​

Delivered​

D4.1

​Scientific report describing TIC biomarker patterns.: Report detailing biomarker patterns associated with

different coagulopathic states in trauma patients.

9

√​

Milestones​

Delivery date (month)​

Delivered​

​MS21

Molecular description of TIC patterns for WP5

9

√​

​MS22

Genetic determinants for TIC for WP8

10

√​

​MS23

Genetic determinants for TIC for WP8

63

√​

Section of Transfusion Medicine Capital Region Blood Bank & Department of Clinical Immunology

Blegdamsvej 9
DK-2100 København Ø

CVR: 29765774

E-mail: contact@tacticgroup.dk